GSK Shingles Vaccine's Next Stop Is CDC Panel After US FDA Approval
Shingrix's 90%-plus efficacy and reduction in postherpetic neuralgia gives GSK's vaccine edge over Merck's Zostavax. CDC advisory committee to vote on lower age for vaccination and use in Zostavax recipients.
You may also be interested in...
In 8-7 vote, Advisory Committee on Immunization Practices recommends GSK's Shingrix as preferred shingles vaccine given its higher efficacy compared to Merck's Zostavax.
US FDA OK for its two-shot shingles regime gives GSK a likely blockbuster with a clear best-in-class profile.
US advisory committee unanimously impressed by the 90% plus efficacy; FDA says label may note lack of data in those who've previously had shingles.